BIOGEN INC. is 3.4x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($28.73 B vs $8.36 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | HALO | BIIB |
|---|---|---|
| Market cap | $8.36 B | $28.73 B |
| US-listed rank | #1040 | #479 |
| Revenue (latest FY) | $1.40B | $9.89B |
| Net income (latest FY) | $316.89M | $1.29B |
| Net margin | 22.7% | 13.1% |
| P/E (trailing FY) | 26.4 | 22.2 |
| SEC filings | 1,481 | 2,690 |
BIOGEN INC. is 3.4x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($28.73 B vs $8.36 B).
In their latest fiscal years, HALOZYME THERAPEUTICS, INC. reported $1.40B in revenue while BIOGEN INC. reported $9.89B.
Full pages: HALOZYME THERAPEUTICS, INC. and BIOGEN INC., or browse the full rankings.